Search results
Pfizer offers up to $250 mln to settle thousands of Zantac cancer lawsuits, FT reports
Reuters via Yahoo Finance· 6 hours agoMay 16 (Reuters) - Pfizer has agreed offer payment of up to $250 million to settle more than 10,000 lawsuits in the United States over cancer risks associated with its now-discontinued ...
... 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for...
WTNH-TV New Haven· 9 hours agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ...
Accelerating Clinical Translation of Antibody-Drug Conjugates with Hybrid AI, Upcoming Webinar...
PRWeb· 22 hours ago/PRNewswire-PRWeb/ -- Bringing a new drug to market costs far too much and takes far too long — and for cancer treatments especially, there is inherent urgency...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 3 days agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Woman's stress as UTI becomes resistant to antibiotics
BBC via AOL· 3 hours agoSian Jones, from Vale of Glamorgan, has spoken about her experience to avoid others feeling...
Years After His Death, a Late Scientist’s Work Has Opened the Door for Life-Saving New Cancer...
SciTechDaily· 1 day agoThe final work of a late scientist from the University of Virginia School of Medicine has paved the...
North Carolina hospitals overcharged patients for oncology drugs: Report
Becker’s Hospital Review· 2 days agoNorth Carolina nonprofit hospitals accused of overcharging for cancer drugs purchased through federal discount program meant for disadvantaged patients
AstraZeneca's COVID prevention drug cuts risk of disease in vulnerable patients
AOL· 4 hours agoThe long-acting antibody therapy called sipavibart showed a "statistically significant reduction" in symptomatic COVID-19 cases among immunocompromised patients, the company said. Immunocompromised ...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga· 3 days agoThe trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab)...
In trial over cancer claims, pharma executive questioned about proper storage, handling of Zantac
Chicago Sun-Times· 2 days agoThe attorneys representing a woman suing the drug makers behind Zantac continued to make the case...